ALX Oncology (ALXO) announced results from a Phase 1b/2 clinical trial demonstrating the company’s investigational CD47-blocker evorpacept in combination with Jazz Pharmaceuticals’ (JAZZ) zanidatamab generates promising anti-tumor activity in patients with both HER2-positive and HER2-low advanced breast cancer. Key trial results to be shared at SABCS 2024 include: HER2-positive by central assessment mBC: Patients in Cohort 1 who were HER2-positive by central assessment showed the greatest anti-tumor activity with a confirmed objective response rate of 55.6% and a median progression free survival of 7.4 months. HER2-positive mBC: Overall, patients in Cohort 1 had a confirmed cORR and mPFS of 33.3% and 3.6 months, respectively. HER2-low mBC: Responses were also observed in Cohort 2. As of the August 2024 data cutoff, median follow-up was 9.6 months, with six patients still on treatment. The median duration of response was not reached for Cohort 1 patients and was 5.5 months for Cohort 2 patients, with responses ongoing, including the longest observed response, in each cohort.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio